Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
66 drugs for “SMA”
Approved 20
- AcalabrutinibASTRAZENECA PLCChronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- CapmatinibNOVARTIS AGCarcinoma, Non-Small-Cell Lung
- CemiplimabREGENERON PHARMACEUTICALS, INC.Advanced Non-Small Cell Lung Cancer; Carcinoma，Non-Small-Cell Lung
- CosibelimabCheckpoint Therapeutics, Inc.Metastatic Non-squamous Non Small Cell Lung Cancer
- DacomitinibPFIZER INCNon-Small Cell Lung Cancer; Non-small Cell Lung Cancer With EGFR-Activating Mutations
- DinutuximabUNITED THERAPEUTICS CorpSmall Cell Lung Cancer
- DurvalumabASTRAZENECA PLCNon-Small Cell Lung Cancer
- LorlatinibPFIZER INCCarcinoma, Non-Small-Cell Lung
- NecitumumabELI LILLY & CoNon Small Cell Lung Cancer
- OsimertinibASTRAZENECA PLCNon-small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung
- RepotrectinibBRISTOL MYERS SQUIBB COCarcinoma, Non-Small-Cell Lung
- RetifanlimabINCYTE CORPMetastatic Nonsquamous Non-Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer
- SelpercatinibELI LILLY & CoCarcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer
- SelumetinibASTRAZENECA PLCLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
- SonrotoclaxBeOne Medicines Ltd.Small Lymphocytic Lymphoma
- SotorasibAMGEN INCNon-Small Cell Lung Cancer (NSCLC)
- TarlatamabAMGEN INCSmall Cell Lung Cancer; Small-cell Lung Cancer; Extensive Stage Small-cell Lung Cancer
- TecovirimatSIGA TECHNOLOGIES INCSmallpox
- Telisotuzumab vedotinAbbVie Inc.Non Small Cell Lung Cancer; Non-Small Cell Lung Cancer
- UblituximabTG THERAPEUTICS, INC.Small Lymphocytic Lymphoma
Phase 3 25
- IvonescimabSummit Therapeutics Inc.Non-Small Cell Lung Cancer · next catalyst 14 Nov 2026
- ABBV-1480AbbVie Inc.Non-Small Cell Lung Cancer
- ABBV-706AbbVie Inc.Small Cell Lung Cancer
- Aglatimagene besadenovecCandel Therapeutics, Inc.Non-squamous, Non-Small Cell Lung Cancer
- AK112Summit Therapeutics Inc.Non-Squamous Non-small Cell Lung Cancer
- AmrubicinAbbVie Inc.Small Cell Lung Cancer
- AZD9291ASTRAZENECA PLCLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer; Stage IB-IIIA Non-small Cell Lung Carcinoma
- BGB-16673BeOne Medicines Ltd.Small Lymphocytic Lymphoma
- BMS-986489BRISTOL MYERS SQUIBB COExtensive-Stage Small Cell Lung Cancer
- CalderasibMerck & Co., Inc.Non-small Cell Lung Cancer
- CeralasertibASTRAZENECA PLCAdvanced or Metastatic Non-Small Cell Lung Cancer
- Eftilagimod alfaIMMUTEP LtdAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- FianlimabREGENERON PHARMACEUTICALS, INC.Advanced Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer
- FirmonertinibArriVent BioPharma, Inc.Advanced Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer
- FurmonertinibArriVent BioPharma, Inc.Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
- Gemcitabine aloneMAIA Biotechnology, Inc.Carcinoma, Non-Small -Cell Lung
- IntismeranMerck & Co., Inc.Non-small Cell Lung Cancer
- Intismeran autogeneMerck & Co., Inc.Carcinoma, Non-Small-Cell Lung; Non-small Cell Lung Cancer
- JDQ443NOVARTIS AGNon-Small Cell Lung Cancer
- LY3537982ELI LILLY & CoCarcinoma, Non-Small-Cell Lung
- MEDI4736ASTRAZENECA PLCNon-Small-Cell Lung Carcinoma NSCLC
- MK-3475AMerck & Co., Inc.Non-small Cell Lung Cancer
- MonalizumabASTRAZENECA PLCNon-Small Cell Lung Cancer
- MRTX849Mirati Therapeutics, Inc.Advanced Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer
- NeladalkibNuvalent, Inc.Non-small Cell Lung Cancer
Phase 2/3 4
- BMS-986504BRISTOL MYERS SQUIBB COMetastatic Non-small Cell Lung Cancer With MTAP Deletion
- BudigalimabAbbVie Inc.Non-Small Cell Lung Cancer
- EIK1001Eikon Therapeutics, Inc.Non Small Cell Lung Cancer (Squamous or Non Squamous)
- LivmoniplimabAbbVie Inc.Non-Small Cell Lung Cancer
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.